^
Association details:
| Biomarker: | ATM biallelic inactivation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4127: Niraparib is active against prostate xenograft models that are wild type or defective for DNA damage repair genes
Published date:
05/15/2020
Excerpt:
To better understand the basis for response to PARP inhibition, nonclinical studies evaluated the efficacy of niraparib in genetically-profiled prostate xenograft models and advanced prostate cancer patient-derived xenograft (PDX) models...In contrast, two ATM biallelic mutant models responded to niraparib treatment with significant TGI and survival benefit.
DOI:
10.1158/1538-7445.AM2020-4127
